Shockwave Medical, Inc. (NASDAQ:SWAV) Receives Average Rating of “Hold” from Brokerages

Shares of Shockwave Medical, Inc. (NASDAQ:SWAVGet Free Report) have received a consensus recommendation of “Hold” from the eleven analysts that are presently covering the firm, MarketBeat reports. Ten investment analysts have rated the stock with a hold rating and one has assigned a buy rating to the company. The average 12 month target price among brokerages that have issued ratings on the stock in the last year is $309.11.

Several analysts have recently issued reports on the stock. Morgan Stanley reissued an “equal weight” rating and set a $335.00 price target (up previously from $285.00) on shares of Shockwave Medical in a research report on Monday, April 8th. Needham & Company LLC reissued a “hold” rating on shares of Shockwave Medical in a research report on Friday, April 5th. Wolfe Research reissued a “peer perform” rating on shares of Shockwave Medical in a research report on Friday, April 5th. Deutsche Bank Aktiengesellschaft reissued a “hold” rating and set a $335.00 price target (up previously from $270.00) on shares of Shockwave Medical in a research report on Monday, April 8th. Finally, Leerink Partnrs lowered shares of Shockwave Medical from an “outperform” rating to a “market perform” rating in a research note on Friday, April 5th.

Check Out Our Latest Stock Analysis on Shockwave Medical

Insider Buying and Selling at Shockwave Medical

In other Shockwave Medical news, insider Isaac Zacharias sold 4,000 shares of the stock in a transaction that occurred on Tuesday, March 26th. The shares were sold at an average price of $287.67, for a total value of $1,150,680.00. Following the transaction, the insider now directly owns 56,818 shares in the company, valued at $16,344,834.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. In other Shockwave Medical news, insider Isaac Zacharias sold 4,000 shares of the stock in a transaction that occurred on Tuesday, March 26th. The shares were sold at an average price of $287.67, for a total value of $1,150,680.00. Following the transaction, the insider now directly owns 56,818 shares in the company, valued at $16,344,834.06. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Laura Francis sold 1,500 shares of the stock in a transaction that occurred on Tuesday, March 26th. The shares were sold at an average price of $300.00, for a total transaction of $450,000.00. Following the completion of the transaction, the director now owns 3,551 shares in the company, valued at $1,065,300. The disclosure for this sale can be found here. 3.40% of the stock is currently owned by insiders.

Hedge Funds Weigh In On Shockwave Medical

Hedge funds have recently modified their holdings of the business. YHB Investment Advisors Inc. purchased a new position in shares of Shockwave Medical during the first quarter worth approximately $28,000. Riverview Trust Co purchased a new position in shares of Shockwave Medical during the first quarter worth approximately $30,000. Rise Advisors LLC acquired a new stake in shares of Shockwave Medical during the first quarter worth $32,000. GAMMA Investing LLC lifted its holdings in shares of Shockwave Medical by 92.9% during the first quarter. GAMMA Investing LLC now owns 135 shares of the company’s stock worth $44,000 after purchasing an additional 65 shares during the period. Finally, Fidelis Capital Partners LLC acquired a new stake in shares of Shockwave Medical during the first quarter worth $45,000. 95.35% of the stock is currently owned by hedge funds and other institutional investors.

Shockwave Medical Stock Performance

NASDAQ SWAV opened at $334.75 on Friday. The firm’s 50-day moving average is $331.90 and its two-hundred day moving average is $273.82. Shockwave Medical has a 12 month low of $157.00 and a 12 month high of $334.90. The company has a debt-to-equity ratio of 0.97, a current ratio of 13.81 and a quick ratio of 12.61. The stock has a market capitalization of $12.57 billion, a P/E ratio of 78.21, a PEG ratio of 2.43 and a beta of 0.88.

Shockwave Medical (NASDAQ:SWAVGet Free Report) last posted its earnings results on Monday, May 6th. The company reported $1.44 EPS for the quarter, beating analysts’ consensus estimates of $0.99 by $0.45. The company had revenue of $218.80 million for the quarter, compared to analysts’ expectations of $207.69 million. Shockwave Medical had a net margin of 20.75% and a return on equity of 24.79%. Shockwave Medical’s revenue for the quarter was up 35.8% compared to the same quarter last year. During the same quarter in the prior year, the company posted $1.03 earnings per share. On average, sell-side analysts anticipate that Shockwave Medical will post 5.05 earnings per share for the current year.

About Shockwave Medical

(Get Free Report

Shockwave Medical, Inc, a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels.

Read More

Analyst Recommendations for Shockwave Medical (NASDAQ:SWAV)

Receive News & Ratings for Shockwave Medical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shockwave Medical and related companies with MarketBeat.com's FREE daily email newsletter.